

New Zealand standardised formulation batch sheet

Flecainide suspension

3		-							
Concentration	20mg/ml	20mg/ml			Storage		Room Temperature		
Expiry date	30 days	30 days			Batch number				
Ora-Blend SF® or Ora-Sweet SF® (s free) can be substituted?			sugar Yes		facturing				
Patient name/NHI:									
Ingredients required and formula: ONLY FOR NEW PATIENTS BEING INITIATED ON FLECAINIDE OR ALREADY STABILISED ON THIS FORMULA									
Ingredient Supplier B		Batch #	Expiry Date		Quantity	Quantity Used	Dispensed	Checked	
Flecainide acetate 100mg tablets					4 tablets				
Ora-Blend®/SF Paddock Labs					to 20ml				
OR									
Ora-Plus® Paddock Labs					10ml				
Ora-Sweet®/SF Paddock Labs					10ml				
Batch Size = 20ml No of Batches to be prepared:					Final volume to				
Extended Batch calculation done by: Extended calculations checked by (Pharmacist):					20ml	ml			
Instructions to compound suspension:									
1. AREA CLEARED FOR PROCESSING BY :									
3. Crush tablets in mortar to a fine powder and add diluent (Ora-Blend® or prepared diluent) to									
form a smooth paste.									
4. Gradually add diluent and transfer to final measuring flask, rinsing mortar well. Mix well.									
5. Make up to final volume and mix well.									
Transfer finished product to pre-rinsed amber plastic medicine bottle and use ClikLok closure if available.									
7. Label appropriately. Additional labels: Shake the bottle. Store at room temperature.									
	. ,						•		
Final yield			ml						
Final check and product release			iture:		Date:				
References:									
Am J Health-Syst Pharm. 1996; 53(18): 2179-2184 Toronto Sick Kids April 2007									

Disclaimer: This batch sheet has been designed to provide guidance and standardised formulations for New Zealand pharmacists. Please note brand changes may impact on the formulation provided. Do not substitute different brands without confirming if this is appropriate. Information was considered accurate at the time of publication and may change as a result of more recent medical developments.

New Zealand ECP Working Group, 2011.

Last updated: August 2011